Skip to main content

Muscular Dystrophy and cannabis in Kentucky

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
30-day supply as certif…
POSSESSION
$25/yr
STATE FEE
14–45 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Kentucky statute and program

The Kentucky Medical Cannabis Program is the operating authority for Kentucky patient certification. The authoritative legal text is: KRS Chapter 218B: Medical Cannabis (SB 47 of 2023).

What the evidence says about cannabis and Muscular Dystrophy

Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.

How to qualify in Kentucky

The Kentucky Medical Cannabis Program requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):

  1. See a Kentucky-licensed medical cannabis practitioner. Under SB 47 (2023), a Kentucky-licensed physician, advanced practice registered nurse, physician assistant, or optometrist who has completed the Kentucky Cabinet for Health and Family Services medical cannabis practitioner course and registered with the Office of Medical Cannabis may certify a patient. Qualifying conditions include any cancer, chronic, severe, intractable, or debilitating pain, epilepsy or other intractable seizure disorder, MS, muscle spasms or spasticity, chronic nausea or cyclical vomiting, and PTSD (KRS 218B.015).
  2. Apply through the Office of Medical Cannabis patient portal. The patient creates an account in the Kentucky Office of Medical Cannabis (OMC) registry portal. The certifying practitioner submits the written certification electronically; the patient then completes the patient registration with a Kentucky driver license or state ID and a passport-style photograph.
  3. Pay the state registration fee. The Kentucky medical cannabis patient registry card fee is $25 annually (caregiver registration is also $25 with a separate background check). Fees are paid online through the OMC portal. The program launched January 1, 2025; patients should expect rule updates during the program’s first operating year.
  4. Receive the card and purchase from a Kentucky dispensary. Kentucky medical cannabis registry cards are issued within roughly 30 days of complete application. Patients may purchase up to a 30-day supply from any licensed Kentucky medical cannabis dispensary. Kentucky does not authorize raw plant material for smoking; permitted forms include edibles, capsules, tinctures, vape products, topicals, and concentrates. Kentucky does not honor out-of-state medical cards.
State registration fee
$25
Physician visit (typical)
$200–$350
Certification to card
14–45 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Kentucky registration steps, fees, and reciprocity rules, see the Kentucky cannabis-laws page.

ICD-10 code

A certifying physician documenting Muscular Dystrophy for the Kentucky medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Kentucky list Muscular Dystrophy as a qualifying condition for medical cannabis?

No. Kentucky's qualifying-condition list does not currently include Muscular Dystrophy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Muscular Dystrophy in Kentucky have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Kentucky program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Kentucky medical marijuana card for Muscular Dystrophy?

Because Kentucky does not currently list Muscular Dystrophy as a qualifying condition, a card for Muscular Dystrophy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Kentucky who is registered with Kentucky Medical Cannabis Program and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Kentucky does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Muscular Dystrophy?

For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. KRS Chapter 218B: Medical Cannabis (SB 47 of 2023)accessed May 16, 2026
  2. Kentucky Cabinet for Health and Family Services: Medical Cannabisaccessed May 16, 2026
  3. Wikipedia: Cannabis in Kentuckyaccessed May 16, 2026
  4. KRS Chapter 218A: Kentucky Controlled Substances Act (possession penalty schedule)accessed May 17, 2026
  5. Kentucky Department of Agriculture: Industrial Hemp Programaccessed May 17, 2026
  6. Kentucky General Assembly bill trackeraccessed May 17, 2026
  7. NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
  8. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea.”

  9. Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
  10. MedlinePlus: Muscular dystrophyaccessed May 18, 2026
  11. FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026